For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

They are the two drugs of the moment, the weight loss products promising a miraculous solution to obesity and—in data ...

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price negotiations; Vinay Prasad to take the helm at the FDA’s Center for Biologics ...

Makers of weight-loss drugs, the hottest segment of the pharmaceutical market just now, weren't looking so hot on the stock exchange Tuesday. A pronouncement from President Trump about the category ...

Kraft Heinz is spending $3 billion to upgrade its U.S. factories, its largest investment in its plants in a decade, even as ...

Shares of American Eagle Outfitters are tumbling before Wednesday's opening bell after the retailer withdrew its financial ...

Welcome to the Relmada Therapeutics first-quarter 2025 earnings call. (Operator Instructions) As a reminder, this conference is being recorded, and will be available for replay on the location website ...